US trade report names countries that fail to adequately protect pharma IPR
This article was originally published in SRA
Executive Summary
The Office of the US Trade Representative has expressed growing concern over problems faced by American pharmaceutical companies in accessing certain markets, particularly in Algeria and Indonesia1,2 In the trade watchdog’s 2009 Special 301 Report, both nations have been elevated to the Priority Watch List, which identifies countries with serious intellectual property problems requiring increased bilateral attention.